Profile data is unavailable for this security.
About the company
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
- Revenue in USD (TTM)17.21m
- Net income in USD-19.72m
- Incorporated2016
- Employees102.00
- LocationImmunoprecise Antibodies Ltd3204-4464 Markham St.VICTORIA V8Z 7X8CanadaCAN
- Phone+1 (604) 806-0626
- Fax+1 (250) 483-0309
- Websitehttps://www.ipatherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | IPA:NMQ since announced | Transaction value |
|---|---|---|
| Carterra Inc-LSA Platform | -66.90% | -- |
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 9.30m | 233.00 | 0.0624 | 0.001 | 2.41 | 0.1313 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Integrated BioPharma, Inc. | 50.32m | 112.00k | 9.63m | 147.00 | 121.21 | 0.5007 | 21.74 | 0.1914 | 0.0026 | 0.0026 | 1.62 | 0.6391 | 1.95 | 4.32 | 10.96 | 342,292.50 | 0.4338 | 13.15 | 0.5505 | 19.97 | 7.72 | 11.22 | 0.2226 | 5.87 | 1.08 | -- | 0.0004 | -- | -0.7006 | 0.1357 | 806.25 | -41.77 | 5.96 | -- |
| Aytu Biopharma Inc | 81.00m | -15.84m | 10.73m | 99.00 | -- | 0.376 | -- | 0.1325 | -2.86 | -2.86 | 14.63 | 4.64 | 0.6364 | 2.15 | 3.08 | 818,202.00 | -12.45 | -27.76 | -25.70 | -46.03 | 67.39 | 58.88 | -19.56 | -56.45 | 0.7916 | -0.0594 | 0.3531 | -- | -24.58 | 61.73 | 7.08 | -- | -- | -- |
| Bio Essence Corp | 593.21k | -1.02m | 12.07m | 12.00 | -- | -- | -- | 20.34 | -0.0278 | -0.0156 | 0.0158 | -0.0458 | 0.3305 | -- | 21.20 | -- | -57.09 | -46.10 | -- | -- | 25.05 | 33.89 | -172.74 | -111.21 | -- | -59.99 | 7.03 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 12.59m | 1.00 | -- | 0.0703 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Bright Green Corp | 0.00 | -9.92m | 13.41m | 5.00 | -- | 1.35 | -- | -- | -0.0538 | -0.0538 | 0.00 | 0.0519 | 0.00 | -- | -- | 0.00 | -47.48 | -- | -72.55 | -- | -- | -- | -- | -- | -- | -- | 0.0494 | -- | -- | -- | 52.54 | -- | -- | -- |
| Immunoprecise Antibodies Ltd | 17.21m | -19.72m | 13.84m | 102.00 | -- | 0.5583 | -- | 0.804 | -0.7454 | -0.7454 | 0.6581 | 0.8598 | 0.3546 | 6.12 | 6.16 | -- | -40.63 | -26.70 | -46.68 | -30.31 | 48.21 | 56.13 | -114.58 | -85.72 | 0.8189 | -134.72 | 0.3289 | -- | 18.65 | 17.54 | -2.32 | -- | 16.71 | -- |
| Onconetix Inc | 1.46m | -53.12m | 14.43m | 12.00 | -- | -- | -- | 9.86 | -104.90 | -104.90 | 2.89 | 50.92 | 0.0328 | 3.45 | 5.30 | 121,979.20 | -119.09 | -- | -215.11 | -- | -57.21 | -- | -3,629.24 | -- | 0.091 | -11.87 | 0.2984 | -- | -- | -- | -176.78 | -- | -- | -- |
| Gelteq Ltd | 0.00 | -1.53m | 15.01m | -- | -- | 1.06 | -- | -- | -0.1605 | -0.1605 | 0.00 | 1.50 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38 | -32.41 | 0.0605 | -- | -- | -- | -72.77 | -- | -- | -- |
| Talphera Inc | 398.00k | -13.70m | 15.12m | 15.00 | -- | 1.19 | -- | 38.00 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 16.53m | 91.00 | -- | 0.6307 | -- | 0.4375 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Marinus Pharmaceuticals Inc | 31.47m | -140.49m | 16.65m | 165.00 | -- | -- | -- | 0.5292 | -2.47 | -2.47 | 0.5524 | -1.21 | 0.238 | 0.6542 | 7.75 | 190,703.00 | -106.26 | -49.64 | -140.93 | -57.76 | 90.17 | -- | -446.49 | -518.96 | 1.47 | -10.06 | -- | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| TherapeuticsMD Inc | 996.00k | -4.83m | 17.27m | 1.00 | -- | 0.6239 | -- | 17.33 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Cara Therapeutics Inc | 11.00m | -111.08m | 17.78m | 55.00 | -- | 1.53 | -- | 1.62 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Data as of Nov 13 2024. Currency figures normalised to Immunoprecise Antibodies Ltd's reporting currency: US Dollar USD
5.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ingalls & Snyder LLCas of 13 Feb 2024 | 1.32m | 4.72% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 63.91k | 0.23% |
| BMO Asset Management Corp.as of 30 Jun 2024 | 55.86k | 0.20% |
| CIBC World Markets, Inc.as of 30 Jun 2024 | 41.20k | 0.15% |
| Desjardins Securities, Inc.as of 30 Jun 2024 | 27.03k | 0.10% |
| Paradice Investment Management LLCas of 31 Mar 2024 | 26.98k | 0.10% |
| Gradient Capital Advisors LLCas of 30 Sep 2024 | 26.81k | 0.10% |
| Northern Trust Global Investments Ltd.as of 30 Jun 2024 | 25.37k | 0.09% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 25.37k | 0.09% |
| Geode Capital Management LLCas of 30 Sep 2024 | 17.48k | 0.06% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
